Latest news with #AuroraCannabis
Yahoo
3 days ago
- Business
- Yahoo
Aurora Cannabis Inc (ACB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Net Revenue: Increased 17% to $98 million. Global Medical Cannabis Revenue: Rose 37% to $64.8 million. International Revenue Growth: Increased 85%. Adjusted Gross Margin: Improved by 1,000 basis points to 52%. Adjusted EBITDA: More than doubled to $10.8 million, a 209% increase. Free Cash Flow: Positive $9.2 million, a 42% increase from the previous year. Cash and Cash Equivalents: $186 million with no cannabis business debt. Consumer Cannabis Net Revenue: Decreased to $7.9 million from $11.5 million. Bevo's Plant Propagation Revenue: Increased to $23.9 million, up 4%. Consolidated Adjusted SG&A: Increased 19% to $37.4 million. Warning! GuruFocus has detected 5 Warning Signs with ACB. Release Date: August 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aurora Cannabis Inc (NASDAQ:ACB) reported a 17% increase in net revenue to $98 million, with global medical cannabis revenue rising by 37% and international revenue growing by 85%. The company achieved an adjusted gross margin improvement of 1,000 basis points to 52%, benefiting from higher cannabis margins. Aurora Cannabis Inc (NASDAQ:ACB) generated positive free cash flow of $9 million and reported an adjusted EBITDA more than doubling to $11 million. The company holds a strong cash position with $186 million in cash and cash equivalents and operates its cannabis business debt-free. Aurora Cannabis Inc (NASDAQ:ACB) is a leader in global medical cannabis, with significant market positions in Canada, Australia, Germany, Poland, and the UK, and is well-positioned to capitalize on new market opportunities. Negative Points Consumer cannabis net revenue decreased to $7.9 million from $11.5 million, reflecting a strategic focus on higher-margin medical cannabis sales. Adjusted SG&A expenses increased by 19% to $37.4 million, driven by higher selling and distribution costs and incremental costs from the acquisition of MedReleaf Australia. Bevo's plant propagation net revenue saw a decrease in adjusted gross margin from 18% to 6% due to inventory write-offs and surplus crops not sold. The company faces potential regulatory changes in Germany, which could impact its operations, although it remains confident in navigating these changes. Aurora Cannabis Inc (NASDAQ:ACB) anticipates significant cash outflows in Q2 2026, which may impact free cash flow results despite expectations of positive annual free cash flow. Q & A Highlights Q: Can you provide more details on the higher SG&A expenses this quarter and how they might trend going forward? A: Miguel Martin, CEO, explained that the increase in SG&A is partly due to variable costs associated with higher revenue, such as shipping and logistics. Additionally, costs related to the integration of MedReleaf Australia have contributed. Simona King, CFO, added that these levels are appropriate, but costs may rise with increased revenue due to variable expenses. Q: With increased competition in Europe, how do you see the margin structure evolving? A: Miguel Martin, CEO, noted that while competition is increasing, Aurora's established presence and certifications in key markets like Poland, the UK, and Germany provide a competitive edge. Each market has unique challenges, but Aurora's infrastructure and strategic positioning allow it to maintain strong margins. Q: Regarding the Bevo liabilities moving to current due to a covenant breach, how will this be resolved? A: Simona King, CFO, clarified that this is an accounting treatment related to Bevo's loan facilities. The issue is being addressed, and they expect it to be resolved quickly without impacting Aurora's audit process. Q: Can you provide guidance on adjusted EBITDA for Q2 2026? A: Simona King, CFO, stated that they expect adjusted EBITDA to remain positive and grow compared to Q1 2026. Q: What potential regulatory changes do you anticipate in Germany, and how might they impact Aurora? A: Miguel Martin, CEO, mentioned that potential regulatory changes in Germany could be announced by the end of the year. While some changes may occur, Aurora's experience and infrastructure position it well to navigate any new regulations, similar to how they managed changes in Poland. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
4 days ago
- Business
- Yahoo
ACB Stock Down as Q1 Earnings Miss Estimates, Revenues Up Y/Y
Aurora Cannabis ACB reported first-quarter fiscal 2026loss per share from continuing operations of 26 cents against the earnings per share (EPS) of 9 cents in the prior-year quarter. The metric missed the Zacks Consensus Estimate of earnings of 18 cents per share. Shares of this company lost nearly 6.1% in today's pre-market hours. The company's shares have gained 8.2% in the year-to-date period compared with the industry's growth of 4.6%. The broader S&P 500 Index has increased 6.9% in the same time frame. Aurora Cannabis Revenue Details The company reported total net revenues of $98 million, up 17.5% year over year. The top line beat the Zacks Consensus Estimate by 38.3%. Revenues were driven by strong momentum in international medical cannabis markets, with higher sales to Australia, Germany, Poland, and the United Kingdom. The company also saw increased revenues in Canada, supported by insurance-covered and self-paying patients. This strategic emphasis on high-margin medical sales helped offset continued declines in the consumer cannabis segment, while modest gains in the plant propagation business added further support. Image Source: Zacks Investment Research Segmental Details Global Medical Cannabis Aurora Cannabis' Global Medical Cannabis segment delivered $64.8 million in revenues, up 37% year over year, and continued to be the company's strongest contributor. This growth was fueled by rising demand across both international and domestic markets. International Medical Cannabis International Medical Cannabis revenues surged 84.7% year over year to $37.1 million, driven by higher sales in Australia, Germany, Poland, and the UK. Aurora Cannabis leveraged its regulatory expertise, GMP-certified facilities, and global supply chain to meet increasing patient needs in these key export markets. Canadian Medical Cannabis The Canadian sub-segment generated $27.7 million in revenues, up 2.1% year over year. Growth was supported by increased purchasing from insurance-covered and self-paying patients. The steady domestic demand, combined with operational efficiency, contributed to maintaining the segment's strong margin profile. Consumer Cannabis Consumer cannabis revenue declined 32% year over year to $7.9 million. The decrease was due to the company's continued decision to prioritize the supply of its GMP-manufactured products to the high-margin global medical cannabis business, rather than the lower-margin consumer segment. The Wholesale Bulk Cannabis segment recorded $1.43 million in net revenue, up from $0.83 million in the year-ago period. Plant Propagation Plant propagation net revenue was wholly comprised of the Bevo business, contributing $23.9 million, up 3.8% from the prior-year period. The increase was a result of organic growth and expanded product offerings, both driven by increased production capacity. Aurora Cannabis Inc. Price, Consensus and EPS Surprise Aurora Cannabis Inc. price-consensus-eps-surprise-chart | Aurora Cannabis Inc. Quote ACB's Margin Trend In the quarter under review, Aurora Cannabis' gross profit declined 34.9% year over year to $27.9 million. However, the adjusted gross margin expanded 1000 basis points to 52%. Selling and marketing expenses increased 3.1% year over year to $14.5 million. General and administration expenses increased 25.8% year over year to $28.6 million. Research and development expenses declined 16% year over year to $0.8 million. Total operating expenses of $48.2 million increased 9.7% year over year. Operating loss for the quarter under review totaled $20.2 million compared with $0.9 million in the prior-year quarter. Financial Position ACB exited the first quarter of fiscal 2026 with cash and cash equivalents of $140.2 million compared with $137.9 million at the fiscal 2025-end. Net cash provided by operating activities at the end of the first quarter was $10.1 million compared with $8.3 million a year ago. Guidance Update Aurora Cannabis expects consolidated net revenue to increase year over year in the fiscal second quarter of 2026, with the primary growth driver anticipated to increase in the range of 8%-12% in Global Medical Cannabis revenue. The Plant Propagation segment is expected to perform in line with traditional seasonal trends, with the company reiterating that 25% to 35% of its annual propagation revenue is typically earned in the second half of the calendar year. ACB's free cash flow is expected to remain positive on a full-year basis. Zacks Rank and Stocks to Consider ACB carries a Zacks Rank #4 (Sell) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. Medpace Holdings, sporting a Zacks Rank of 1 (Strong Buy), reported second-quarter 2025 EPS of $3.10, beating the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Globe and Mail
6 days ago
- Business
- Globe and Mail
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
Aurora Cannabis ACB is slated to release first-quarter fiscal 2026 results on Aug. 6, before market open. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cents per share and $70.88 million, respectively. The earnings estimate, which has remained stable over the past seven days, indicates a whopping 263.6% growth year over year. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year increase of 5.4%. The consensus mark for fiscal 2026 revenues is pegged at $272.1 million, implying a rise of 7.6% year over year, and the same for EPS is pinned at 56 cents, suggesting a year-over-year improvement of 100%. This medical cannabis producer's earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missing once, delivering an average surprise of 50.10%. Q2 Earnings Whispers for Aurora Cannabis Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below. Earnings ESP: ACB has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Factors to Note Ahead of ACB's Q2 Results Aurora Cannabis is slated to report fiscal first-quarter 2026 results later this week, following a record-setting fiscal 2025 driven by its focused 'medical-first' strategy. The upcoming results are expected to reflect sustained momentum in global medical cannabis sales, supported by expanded product offerings, ongoing international market penetration and operational excellence. Australia continues to be a key growth lever, where Aurora Cannabis recently expanded its IndiMed portfolio with the launch of TEMPO 22 cultivars, catering to rising patient demand for high-potency, value-segment medical cannabis. The company's deep-rooted infrastructure and longstanding relationships in the region have fortified its second-highest market share position, with management optimistic about further patient accessibility and product uptake. This is likely to have boosted top-line growth in the soon-to-be-reported quarter. In Europe, strong performance in Germany is likely to have led the top-line growth during the fiscal first quarter, benefiting from cannabis de-scheduling and increasing patient registrations. Aurora Cannabis' strategic focus on ensuring consistent product availability has been crucial, while the ramp-up of German-cultivated IndiMed offerings must have further cemented its leadership. Sales are likely to have been hurt by temporary regulatory headwinds in Poland. However, management remains bullish on the market's long-term growth prospects, underpinned by planned launches of high-quality cultivars. Additionally, the U.K. business is expected to have gained traction from the launch of inhalable cannabis concentrates, an innovative format catering to evolving patient needs. These product introductions mark another step in Aurora Cannabis' mission to diversify dosage forms and enhance patient access in global markets. On the operational front, the recent $3 million upgrade to Aurora Cannabis' Alpine facility in British Columbia has doubled yields and potency, which might have supported top-line growth with a new supply line in place. While management anticipates first-quarter revenues to be slightly lower than the fourth-quarter fiscal 2025 level due to temporary international market fluctuations, margins are expected to remain robust, supported by a favorable product mix and continued cost discipline. Adjusted EBITDA is projected to moderate sequentially but remain positive, maintaining Aurora Cannabis' position as one of the few profitable global cannabis players. ACB Price Performance & Valuation On a year-to-date basis, shares of ACB have gained 5.4%, outperforming its close peers, Tilray Brands TLRY and Canopy Growth CGC and the Medical Products industry. In terms of valuation, Aurora Cannabis trades at a forward 12-month P/S of 0.9 — above Tilray Brands (0.65) and below Canopy Growth (1.07). Despite Tilray Brands offering lower multiples, ACB's premium reflects stronger growth expectations. Moreover, a higher valuation of Canopy Growth despite its declining share price makes it an expensive choice. ACB vs TLRY Image Source: Zacks Investment Research ACB vs CGC Buy Aurora Cannabis Stock Ahead of Q2 Results? While Aurora Cannabis continues to demonstrate strong execution in its global medical cannabis strategy, near-term headwinds warrant a cautious stance. Temporary regulatory disruptions in Poland, competitive pressures in international markets, and the anticipated sequential revenue dip in first-quarter fiscal 2026 temper immediate upside potential. Additionally, while Aurora Cannabis' margin profile remains industry-leading, further scalability in high-margin markets is essential to drive meaningful top-line growth. With the stock's recent gains reflecting much of the operational improvements, it would be wise for investors to await clearer visibility on sustained revenue acceleration and international market stabilization. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC): Free Stock Analysis Report Tilray Brands, Inc. (TLRY): Free Stock Analysis Report Aurora Cannabis Inc. (ACB): Free Stock Analysis Report
Yahoo
02-08-2025
- Business
- Yahoo
Aurora Cannabis Inc. (ACB) Becomes Medical Market Powerhouse with 93% Sales Jump
We recently compiled a list of the 12 Cheap Pot Stocks to Buy According to Hedge Funds. Aurora Cannabis Inc. stands fourth on our list. Aurora Cannabis Inc. (NASDAQ:ACB), a prominent Canadian medical cannabis company, is strengthening its global footprint by focusing on international markets, particularly in Europe and Australia. The company has shifted away from recreational cannabis, positioning itself as a leader in the medical segment with strong fiscal results, reporting a 93% year-over-year increase in global medical cannabis revenue, which has now surpassed its domestic Canadian sales. Australia has become a key growth market where the company ranks as the second-largest supplier, while Germany's progressive cannabis laws offer further expansion opportunities. Aurora Cannabis Inc. (NASDAQ:ACB)'s growing international presence and improving fundamentals have placed it among cheap pot stocks to buy, especially for investors seeking value in the medical cannabis space. Its international growth is underpinned by a debt-free cannabis business, positive adjusted EBITDA, and a renewed focus on profitability, marking a notable turnaround. The company continues to engage shareholders, with its 2025 Annual General and Special Meeting scheduled for August 8. A laboratory filled with medical cannabis research equipment and supplies. Beyond financials, the business remains committed to social responsibility through initiatives like 'Strains for Heroes,' which develops medical cannabis products for veterans in collaboration with the community. Five percent of net profits from these products are donated to veteran-focused organizations, demonstrating the company's commitment to both innovation and impact. While we acknowledge the potential of ACB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-07-2025
- Business
- Yahoo
E-Commerce Surge Boosting Expansion, SoRSE Emulsion Technology Enhancing Cannabis Beverage Experience
The Cannabis-Infused Products Market is set for exponential growth, reaching $78.51 billion by 2029 at a CAGR of 23.4%. Key factors include increasing legalization, consumer demand for wellness solutions, and innovative technologies like SōRSE emulsion. Major players include Curaleaf, Aurora Cannabis, and Tilray. North America leads the market. Cannabis-Infused Products Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Cannabis-Infused Products Market Report 2025" report has been added to cannabis-infused products market size has grown exponentially in recent years. It will grow from $27.37 billion in 2024 to $33.85 billion in 2025 at a compound annual growth rate (CAGR) of 23.7%. The cannabis-infused products market size is expected to see exponential growth in the next few years. It will grow to $78.51 billion in 2029 at a compound annual growth rate (CAGR) of 23.4%. This Cannabis-Infused Products Market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. The growth during the historic period can be attributed to the increasing legalization of cannabis, growing consumer awareness, a rise in medical cannabis applications, innovations in product formulations, and the expansion of distribution growth during the forecast period can be attributed to ongoing legalization trends, rising demand for wellness products, increasing investment in research and development, growing acceptance of CBD products, and the expansion of e-commerce platforms. Key trends in the forecast period include the use of nanotechnology for better absorption, advanced extraction techniques, the development of cannabis-based beverages, AI-driven product innovation, and the adoption of blockchain for supply chain growth of e-commerce is expected to drive the expansion of the cannabis-infused products market in the future. E-commerce refers to the buying and selling of goods and services over the internet, facilitating transactions through online platforms and digital payment systems. This sector is growing due to increased internet penetration, shifting consumer preferences for online shopping, and advancements in digital payment solutions, making online shopping more convenient and accessible. Cannabis-infused products are benefiting from e-commerce by meeting the rising demand for wellness and alternative health solutions. They offer a variety of products that can be easily accessed, purchased, and delivered through online platforms. For example, in May 2024, the United States Census Bureau reported that U.S. retail e-commerce sales reached $289.2 billion in the first quarter of 2024, marking a 2.1% increase compared to the fourth quarter of 2023. This growth in e-commerce is contributing to the expansion of the cannabis-infused products in the cannabis-infused products market are focusing on innovative technologies, such as SoRSE emulsion technology, to improve the bioavailability and taste of cannabis-infused beverages and edibles, enhancing the overall consumer experience. SoRSE emulsion technology is a patented water-soluble emulsion platform designed to improve the bioavailability, stability, and sensory experience of cannabis and other functional ingredients in consumable products. For instance, in January 2024, Aurora Cannabis Inc., a Canada-based cannabis company, launched a new line of cannabis-infused beverages, including Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz. These beverages combine precise dosage control with the convenience of a drink, allowing consumers to enjoy consistent effects in an easy-to-consume form. They utilize SoRSE emulsion technology, ensuring better bioavailability of cannabinoids, which leads to faster onset times and more predictable effects. The beverages also feature a smooth taste that masks the natural bitterness of cannabis, appealing to both seasoned users and December 2024, Organigram Holdings Inc., a Canada-based company specializing in the production of medical cannabis products, acquired Motif Labs Ltd. for an undisclosed amount. This acquisition aims to strengthen Organigram's market position, broaden its product range, and enhance its capabilities in the cannabis-infused products segment, solidifying its leadership in the Canadian cannabis industry. Motif Labs Ltd. is a Canadian company known for producing high-quality cannabis extracts and innovative America was the largest region in the cannabis-infused products market in 2024. The regions covered in cannabis-infused products report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cannabis-infused products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Attributes: Report Attribute Details No. of Pages 175 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $33.85 Billion Forecasted Market Value (USD) by 2029 $78.51 Billion Compound Annual Growth Rate 23.4% Regions Covered Global Key Topics Covered: 1. Executive Summary2. Cannabis-Infused Products Market Characteristics3. Cannabis-Infused Products Market Trends and Strategies4. Cannabis-Infused Products Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market5. Global Cannabis-Infused Products Growth Analysis and Strategic Analysis Framework5.1. Global Cannabis-Infused Products PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)5.2. Analysis of End Use Industries5.3. Global Cannabis-Infused Products Market Growth Rate Analysis5.4. Global Cannabis-Infused Products Historic Market Size and Growth, 2019-2024, Value ($ Billion)5.5. Global Cannabis-Infused Products Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)5.6. Global Cannabis-Infused Products Total Addressable Market (TAM)6. Cannabis-Infused Products Market Segmentation6.1. Global Cannabis-Infused Products Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Skincare Cosmetics Haircare Intimate Lubricants Gummies Pills Infused Beverages 6.2. Global Cannabis-Infused Products Market, Segmentation by Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hemp Marijuana 6.3. Global Cannabis-Infused Products Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion B2B B2C 6.4. Global Cannabis-Infused Products Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Medical Personal Use Pharmaceuticals Wellness 6.5. Global Cannabis-Infused Products Market, Sub-Segmentation of Skincare, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Lotions Cannabis-Infused Face Serums Hemp-Infused Moisturizers 6.6. Global Cannabis-Infused Products Market, Sub-Segmentation of Cosmetics, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Cannabis-Infused Foundations CBD-Infused Lip Balms Hemp-Infused Mascaras 6.7. Global Cannabis-Infused Products Market, Sub-Segmentation of Haircare, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Shampoos Cannabis-Infused Conditioners Hemp-Infused Hair Oils 6.8. Global Cannabis-Infused Products Market, Sub-Segmentation of Intimate Lubricants, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD-Infused Lubricants THC-Infused Lubricants Hybrid Cannabis Lubricants 6.9. Global Cannabis-Infused Products Market, Sub-Segmentation of Gummies, by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion CBD Gummies THC Gummies Full-Spectrum Cannabis Gummies 7. Cannabis-Infused Products Market Regional and Country Analysis7.1. Global Cannabis-Infused Products Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion7.2. Global Cannabis-Infused Products Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Cannabis-Infused Products Market Competitive Landscape and Company Profiles Curaleaf Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis Trulieve Cannabis Corp. Overview, Products and Services, Strategy and Financial Analysis Green Thumb Industries Inc. Overview, Products and Services, Strategy and Financial Analysis Cresco Labs Inc. Overview, Products and Services, Strategy and Financial Analysis Tilray Inc. Overview, Products and Services, Strategy and Financial Analysis Cannabis-Infused Products Market Other Major and Innovative Companies Columbia Care Inc. Canopy Growth Corporation MedMen Enterprises Inc. Aurora Cannabis Inc. Eaze Inc. Pax Labs Flow Kana Inc. Kiva Brands Inc. Charlotte's Web Holdings Inc. Vireo Health International Inc. The Green Organic Dutchman Holdings Ltd. Indus Holdings Inc. THC Design Inc. Herbivore Botanicals Baked Bros LLC For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cannabis-Infused Products Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
